
Invivyd Investor Relations Material
Latest events

Q1 2025
Invivyd
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Invivyd Inc
Access all reports
Invivyd Inc., a clinical-stage biopharmaceutical company, is focused to the discovery, development, and commercialization of antibody-based solutions targeting infectious diseases, with a primary focus on the United States. The company's mission centers on delivering antibody-based therapies to protect vulnerable populations against circulating viral threats, such as SARS-CoV-2, leveraging advanced antibody engineering and viral surveillance techniques. Invivyd's lead product candidate, adintrevimab, is a neutralizing antibody undergoing clinical trials for both treatment and prevention of coronavirus disease. Additionally, the company is developing monoclonal antibody candidates, including VYD222 and VYD224, aimed at offering neutralizing protection against SARS-CoV-2, alongside discovery stage candidates for seasonal influenza prevention. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Key slides for Invivyd Inc


Q1 2025
Invivyd Inc


Q2 2024
Invivyd Inc
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
IVVD
Country
🇺🇸 United States